You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

~ Buy the FOLOTYN (pralatrexate) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR FOLOTYN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for FOLOTYN

Trial IDTitleStatusSponsorPhaseStart DateSummary
NCT00481871 ↗ Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies Completed Acrotech Biopharma LLC Phase 1/Phase 2 2007-05-01 This study is for patients with lymphoproliferative malignancies that have progressed after receiving a previous treatment (relapsed) or are no longer responding to treatment (refractory). To be in this study, patients must have certain types of Hodgkin's lymphoma (HL), peripheral T-cell lymphoma (PTCL), or B-cell lymphoma, including Waldenstrom's macroglobulinemia. This study is being done to find doses of the combination of pralatrexate and gemcitabine with vitamin B12 and folic acid that can be safely given to patients with these types of lymphoma and explore the effectiveness of the treatment.
NCT00052442 ↗ 10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma Completed Memorial Sloan Kettering Cancer Center Phase 1/Phase 2 2002-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 10-propargyl-10-deazaaminopterin in treating patients who have recurrent or refractory non-Hodgkin's lymphoma or Hodgkin's lymphoma.
NCT00052442 ↗ 10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma Completed National Cancer Institute (NCI) Phase 1/Phase 2 2002-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 10-propargyl-10-deazaaminopterin in treating patients who have recurrent or refractory non-Hodgkin's lymphoma or Hodgkin's lymphoma.
NCT00052442 ↗ 10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma Completed Spectrum Pharmaceuticals, Inc Phase 1/Phase 2 2002-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 10-propargyl-10-deazaaminopterin in treating patients who have recurrent or refractory non-Hodgkin's lymphoma or Hodgkin's lymphoma.
>Trial ID>Title>Status>Phase>Start Date>Summary
Showing 1 to 4 of 4 entries

Clinical Trial Conditions for FOLOTYN

Condition Name

3222000.511.522.53Peripheral T-cell LymphomaAnaplastic Large Cell LymphomaNon-small Cell Lung CancerLymphoma[disabled in preview]
Condition Name for FOLOTYN
Intervention Trials
Peripheral T-cell Lymphoma 3
Anaplastic Large Cell Lymphoma 2
Non-small Cell Lung Cancer 2
Lymphoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

16119600246810121416LymphomaLymphoma, T-CellLymphoma, T-Cell, PeripheralLymphoma, Non-Hodgkin[disabled in preview]
Condition MeSH for FOLOTYN
Intervention Trials
Lymphoma 16
Lymphoma, T-Cell 11
Lymphoma, T-Cell, Peripheral 9
Lymphoma, Non-Hodgkin 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for FOLOTYN

Trials by Country

+
Trials by Country for FOLOTYN
Location Trials
United States 84
United Kingdom 7
India 7
France 7
Hungary 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

+
Trials by US State for FOLOTYN
Location Trials
New York 12
California 8
Texas 6
New Jersey 5
Illinois 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for FOLOTYN

Clinical Trial Phase

5.6%16.7%50.0%27.8%0123456789Phase 4Phase 3Phase 2[disabled in preview]
Clinical Trial Phase for FOLOTYN
Clinical Trial Phase Trials
Phase 4 1
Phase 3 3
Phase 2 9
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

65.2%17.4%13.0%00246810121416CompletedRecruitingWithdrawn[disabled in preview]
Clinical Trial Status for FOLOTYN
Clinical Trial Phase Trials
Completed 15
Recruiting 4
Withdrawn 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for FOLOTYN

Sponsor Name

trials02468101214Spectrum Pharmaceuticals, IncAcrotech Biopharma LLCNational Cancer Institute (NCI)[disabled in preview]
Sponsor Name for FOLOTYN
Sponsor Trials
Spectrum Pharmaceuticals, Inc 14
Acrotech Biopharma LLC 8
National Cancer Institute (NCI) 5
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

58.0%32.0%10.0%0051015202530IndustryOtherNIH[disabled in preview]
Sponsor Type for FOLOTYN
Sponsor Trials
Industry 29
Other 16
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

FOLOTYN: Clinical Trials, Market Analysis, and Projections

Introduction to FOLOTYN

FOLOTYN, also known as pralatrexate, is a folate analog metabolic inhibitor used in the treatment of peripheral T-cell lymphoma (PTCL). It is marketed by Acrotech Biopharma and has shown significant efficacy in both newly diagnosed and relapsed or refractory PTCL cases.

Clinical Trials Overview

Phase 1 Trial: Pralatrexate Combined with CHOP

A recent phase 1 trial investigated the combination of pralatrexate with the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone) for newly diagnosed PTCL patients. The trial was conducted in two parts: the first part involved dose escalation to determine the maximum tolerated dose (MTD) of pralatrexate, and the second part involved an expansion cohort treated at the MTD.

  • Dose Escalation: Patients were treated with pralatrexate doses ranging from 10 to 30 mg/m² in combination with CHOP. No dose-limiting toxicities (DLTs) were observed in any of the cohorts, and the 30 mg/m² dose was selected for the expansion cohort[1][4].
  • Expansion Cohort: The expansion cohort consisted of 33 additional patients treated with the Fol-CHOP regimen (pralatrexate 30 mg/m² + CHOP). The overall response rate (ORR) was 83.9%, with 20 complete responses and 6 partial responses. The regimen was generally well tolerated, despite common adverse events such as anemia, neutropenia, and febrile neutropenia[1][4].

Phase II Trial: Relapsed or Refractory PTCL

A Phase II, single-arm, multicenter clinical trial (PDX-008) evaluated the efficacy of pralatrexate in patients with relapsed or refractory PTCL. The trial demonstrated an ORR of 27%, with a median duration of response of 287 days. The complete response rate was 8%, and several patients who had not responded to prior therapies showed a response to pralatrexate[3].

Market Analysis

Current Market Status

FOLOTYN is approved in several countries, including the United States, Japan, and China, for the treatment of relapsed or refractory PTCL. The drug has shown promising results in clinical trials, making it a valuable option for patients with limited treatment choices.

  • Approval and Authorization: Health Canada approved FOLOTYN under the Notice of Compliance with Conditions (NOC/c) Guidance, highlighting its favorable benefit-harm-uncertainty profile. The approval was based on response rates demonstrated in clinical trials, although further follow-up is required to confirm long-term benefits[3].

Market Expansion

CASI Pharmaceuticals, Inc. has recently initiated the administration of FOLOTYN in China, marking a significant step in addressing critical medical needs in the Chinese market. This expansion is part of CASI’s strategy to become a leader in the Greater China market[5].

  • Chinese Registrational Study: The study in China showed an ORR of 52% and a median progression-free survival (PFS) of 4.8 months, which is more favorable compared to the PROPEL study in the US[5].

Projections and Future Outlook

Generic Entry

FOLOTYN is currently protected by two US patents, with the earliest potential generic entry date estimated to be May 31, 2025. This date may be subject to change due to patent challenges or generic licensing agreements[2].

  • Patent Landscape: The drug has 31 patent family members in 23 countries, indicating a robust patent protection strategy. However, the high interest in generic entry, as evidenced by patent litigation cases, suggests that generic competition may arise soon after the patent expiration[2].

Market Growth

Given its efficacy and the growing need for effective treatments in PTCL, FOLOTYN is expected to maintain a strong market presence until generic versions become available.

  • Clinical Benefits: The drug’s ability to selectively enter cancer cells and inhibit key enzymes involved in DNA replication makes it a promising treatment option. The high ORR and manageable safety profile further support its market potential[1][3][4].

Future Clinical Investigations

The Fol-CHOP regimen is deemed worthy of further investigation, particularly for newly diagnosed PTCL patients. Ongoing and future clinical trials will continue to evaluate the long-term efficacy and safety of pralatrexate in combination with other chemotherapeutic agents[1][4].

Key Takeaways

  • Clinical Efficacy: FOLOTYN has demonstrated high response rates in both newly diagnosed and relapsed or refractory PTCL patients.
  • Market Expansion: The drug is being introduced in new markets, such as China, to address critical medical needs.
  • Patent Protection: Current patent protections are set to expire in 2025, which may lead to generic competition.
  • Future Investigations: Ongoing and future trials will focus on the long-term benefits and safety of the Fol-CHOP regimen.

FAQs

What is FOLOTYN used for?

FOLOTYN (pralatrexate) is used for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) and is also being investigated for newly diagnosed PTCL in combination with the CHOP regimen[1][3][5].

What are the key findings from the clinical trials of FOLOTYN?

Clinical trials have shown that FOLOTYN has a high overall response rate (ORR) in PTCL patients. For newly diagnosed PTCL, the ORR was 83.9% when combined with CHOP, and for relapsed or refractory PTCL, the ORR was 27% in a Phase II trial[1][3][4].

When is the generic version of FOLOTYN expected to enter the market?

The earliest potential generic entry date for FOLOTYN is estimated to be May 31, 2025, subject to changes due to patent challenges or licensing agreements[2].

What are the common adverse events associated with FOLOTYN?

Common adverse events include anemia, neutropenia, febrile neutropenia, fatigue, mucosal inflammation, nausea, and vomiting[1][4].

Is FOLOTYN approved in multiple countries?

Yes, FOLOTYN is approved in several countries, including the United States, Japan, and China, for the treatment of relapsed or refractory PTCL[3][5].

What is the mechanism of action of FOLOTYN?

FOLOTYN works by selectively entering cells expressing reduced folate carrier type 1 (RFC-1) and competitively inhibiting dihydrofolate reductase, leading to the inhibition of RNA synthesis and DNA replication in cancer cells[3][4].

Sources

  1. Pralatrexate injection combined with CHOP for treatment of PTCL. Blood Advances, 2024.
  2. FOLOTYN Drug Patent Profile. DrugPatentWatch.
  3. Summary Basis of Decision for Folotyn. Health Canada.
  4. Pralatrexate injection combined with CHOP for treatment of PTCL. PubMed, 2024.
  5. CASI Pharmaceuticals Announces First Dosing of FOLOTYN® in China. Biospace, 2024.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.